These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12353320)

  • 1. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
    Barton JC; Jones SC; Lamberth WC; Reymann MT; Scott VC
    Am J Hematol; 2002 Oct; 71(2):139-40. PubMed ID: 12353320
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
    Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
    Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
    Miyazawa K; Nishimaki J; Katagiri T; Sashida G; Shoji N; Kawakubo K; Suzuki A; Shimamoto T; Gotoh A; Kuriyama Y; Ito Y; Tauchi T; Kawanishi Y; Kimura Y; Ohyashiki K
    Int J Hematol; 2003 Jan; 77(1):93-5. PubMed ID: 12568307
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 7. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 8. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
    Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
    Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
    [No Abstract]   [Full Text] [Related]  

  • 9. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 10. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D; Lipton J
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis.
    Kyathari S; Chao K; Liu D; Seiter K
    Leuk Lymphoma; 2008 May; 49(5):1002-4. PubMed ID: 18452084
    [No Abstract]   [Full Text] [Related]  

  • 12. Precipitation of porphyria cutanea tarda by imatinib mesylate?
    Ho AY; Deacon A; Osborne G; Mufti GJ
    Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
    [No Abstract]   [Full Text] [Related]  

  • 13. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 15. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K; Potti A; Mehdi SA
    J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
    [No Abstract]   [Full Text] [Related]  

  • 16. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
    Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
    Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
    [No Abstract]   [Full Text] [Related]  

  • 17. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
    Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract]   [Full Text] [Related]  

  • 18. Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.
    Aduwa E; Szydlo R; Marin D; Foroni L; Reid A; Goldman J; Apperley JF; Milojkovic D
    Blood; 2012 Dec; 120(25):5087-8. PubMed ID: 23243158
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
    Rajda J; Phatak PD
    Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
    [No Abstract]   [Full Text] [Related]  

  • 20. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
    Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.